Northern Trust Corp Cue Biopharma, Inc. Transaction History

Northern Trust Corp

  • $709 Billion
  • Q2 2025

A detailed history of Northern Trust Corp transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 132,573 shares of CUE stock, worth $104,732. This represents 0.0% of its overall portfolio holdings.

Number of Shares
132,573
Previous 196,629 32.58%
Holding current value
$104,732
Previous $178,000 49.44%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025
SELL
$0.58 - $0.86 $37,152 - $55,088
-64,056 Reduced 32.58%
132,573 $90,000
Q1 2025

May 13, 2025
SELL
$0.91 - $1.75 $10,535 - $20,259
-11,577 Reduced 5.56%
196,629 $178,000
Q4 2024

Feb 14, 2025
BUY
$0.71 - $1.88 $49,623 - $131,396
69,892 Added 50.53%
208,206 $214,000
Q3 2024

Nov 13, 2024
SELL
$0.45 - $1.08 $95,447 - $229,073
-212,105 Reduced 60.53%
138,314 $105,000
Q2 2024

Aug 14, 2024
SELL
$1.24 - $2.18 $18,306 - $32,183
-14,763 Reduced 4.04%
350,419 $434,000
Q1 2024

May 14, 2024
SELL
$1.77 - $3.09 $28,647 - $50,011
-16,185 Reduced 4.24%
365,182 $690,000
Q4 2023

Feb 13, 2024
BUY
$1.72 - $3.1 $90,613 - $163,314
52,682 Added 16.03%
381,367 $1.01 Million
Q3 2023

Nov 13, 2023
SELL
$2.23 - $4.69 $6,132 - $12,897
-2,750 Reduced 0.83%
328,685 $755,000
Q2 2023

Aug 11, 2023
BUY
$3.11 - $4.91 $787,249 - $1.24 Million
253,135 Added 323.29%
331,435 $1.21 Million
Q1 2023

May 15, 2023
BUY
$2.41 - $3.74 $37,863 - $58,759
15,711 Added 25.1%
78,300 $279,000
Q3 2022

Nov 14, 2022
BUY
$2.23 - $3.37 $4,716 - $7,127
2,115 Added 3.5%
62,589 $139,000
Q2 2022

Aug 12, 2022
SELL
$2.49 - $5.92 $607,241 - $1.44 Million
-243,872 Reduced 80.13%
60,474 $150,000
Q1 2022

May 13, 2022
SELL
$4.41 - $12.28 $53,453 - $148,845
-12,121 Reduced 3.83%
304,346 $1.49 Million
Q4 2021

Feb 08, 2022
BUY
$10.86 - $17.85 $72,729 - $119,541
6,697 Added 2.16%
316,467 $3.58 Million
Q3 2021

Nov 15, 2021
SELL
$10.06 - $15.3 $96,022 - $146,038
-9,545 Reduced 2.99%
309,770 $4.51 Million
Q2 2021

Aug 13, 2021
SELL
$10.9 - $14.53 $124,031 - $165,336
-11,379 Reduced 3.44%
319,315 $3.72 Million
Q1 2021

May 12, 2021
SELL
$11.2 - $16.09 $146,171 - $209,990
-13,051 Reduced 3.8%
330,694 $4.04 Million
Q4 2020

Feb 11, 2021
SELL
$11.12 - $16.4 $42,111 - $62,106
-3,787 Reduced 1.09%
343,745 $4.3 Million
Q3 2020

Nov 16, 2020
SELL
$15.05 - $23.54 $55,474 - $86,768
-3,686 Reduced 1.05%
347,532 $5.23 Million
Q2 2020

Aug 14, 2020
BUY
$12.7 - $30.73 $1.46 Million - $3.53 Million
114,744 Added 48.52%
351,218 $8.61 Million
Q1 2020

May 14, 2020
BUY
$9.85 - $22.27 $161,549 - $365,250
16,401 Added 7.45%
236,474 $3.36 Million
Q4 2019

Feb 14, 2020
SELL
$7.06 - $17.47 $25,267 - $62,525
-3,579 Reduced 1.6%
220,073 $3.49 Million
Q3 2019

Nov 13, 2019
BUY
$6.78 - $9.28 $129,477 - $177,220
19,097 Added 9.34%
223,652 $1.89 Million
Q2 2019

Aug 13, 2019
BUY
$7.18 - $9.65 $28,504 - $38,310
3,970 Added 1.98%
204,555 $1.84 Million
Q1 2019

May 13, 2019
BUY
$4.7 - $9.29 $51,761 - $102,310
11,013 Added 5.81%
200,585 $1.55 Million
Q4 2018

Feb 12, 2019
SELL
$4.35 - $8.73 $6,094 - $12,230
-1,401 Reduced 0.73%
189,572 $891,000
Q3 2018

Nov 14, 2018
BUY
$7.91 - $11.89 $82,952 - $124,690
10,487 Added 5.81%
190,973 $1.73 Million
Q2 2018

Aug 14, 2018
BUY
$10.93 - $14.48 $1.15 Million - $1.53 Million
105,333 Added 140.16%
180,486 $2.14 Million
Q1 2018

May 09, 2018
BUY
$11.63 - $17.25 $874,029 - $1.3 Million
75,153 New
75,153 $1.06 Million

Others Institutions Holding CUE

# of Institutions
48
Shares Held
17.7M
Call Options Held
0
Put Options Held
0
View Full List

About Cue Biopharma, Inc.

CUE Quotes by TradingView
  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $28M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email